Patients with heart failure of mostly ischemic etiology were found to have increased burden of mendelian cardiomyopathy variants compared with control individuals.
Risk for heart failure hospital presentations significantly lower in statin-exposed women treated with anthracyclines.
The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.
Underlying heart disease and use of ACE inhibitors were found to be significant predictors of response to cardiac resynchronization therapy upgrade in patients with chronic right ventricular pacing.
Expert Consensus Decision Pathway provides guidance on same-day discharge of patients who have undergone PCI.
Invasive assessment of cardiopulmonary hemodynamics may predict survival after transcatheter tricuspid edge-to-edge valve repair in patients with severe tricuspid regurgitation and symptomatic heart failure.
In patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation, early extracorporeal membrane oxygenation-facilitated resuscitation was found to improve survival to hospital discharge.
High-SES patients less likely to receive delayed cardiopulmonary resuscitation; more likely to survive CPR, to survive to discharge and to 30 days.
Researchers’ goal was to determine empagliflozin’s impact on the central hemodynamic parameters of patients with heart failure with reduced ejection fraction.
Peripheral lymphatic vessels may not compensate for interstitial accumulation and fluid extravasation in HFpEF.